Chemomab Therapeutics Ltd.
CMMB
$1.23
$0.000.00%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -38.75% | -20.75% | 38.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -10.77% | 21.42% | 101.79% |
| Operating Income | -- | -- | 10.77% | -21.42% | -101.79% |
| Income Before Tax | -- | -- | 14.05% | -16.48% | -100.33% |
| Income Tax Expenses | -- | -- | 100.00% | 101.84% | -- |
| Earnings from Continuing Operations | -- | -- | 12.39% | -19.12% | -97.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 12.39% | -19.12% | -97.10% |
| EBIT | -- | -- | 10.77% | -21.42% | -101.79% |
| EBITDA | -- | -- | 10.83% | -21.43% | -101.91% |
| EPS Basic | -- | -- | 12.83% | -21.16% | -97.42% |
| Normalized Basic EPS | -- | -- | 28.61% | -2.46% | -100.60% |
| EPS Diluted | -- | -- | 12.83% | -21.16% | -97.42% |
| Normalized Diluted EPS | -- | -- | 28.61% | -2.46% | -100.60% |
| Average Basic Shares Outstanding | -- | -- | 3.19% | -0.94% | 0.32% |
| Average Diluted Shares Outstanding | -- | -- | 3.19% | -0.95% | 0.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |